{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:12:26Z","timestamp":1777529546108,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.cellimm.2015.09.007","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T10:52:51Z","timestamp":1443264771000},"page":"8-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["T cell response to FVIII"],"prefix":"10.1016","volume":"301","author":[{"given":"Marc","family":"Jacquemin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Saint-Remy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2015.09.007_b0005","first-page":"1","article-title":"Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients","volume":"31","author":"Hoyer","year":"1994","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.cellimm.2015.09.007_b0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/217174a0","article-title":"Gamma G4-globulin antibody causing inhibition of clotting factor VIII","volume":"217","author":"Andersen","year":"1968","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2015.09.007_b0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V92.2.496","article-title":"Mechanisms and kinetics of fVIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor","volume":"92","author":"Jacquemin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2015.09.007_b0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood.V95.2.558","article-title":"Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes","volume":"95","author":"van den Brink","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2015.09.007_b0025","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/381751a0","article-title":"Clonal selection and learning in the antibody system","volume":"381","author":"Rajewsky","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2015.09.007_b0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.2830420408","article-title":"Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the multi-center hemophilia cohort study","volume":"42","author":"Bray","year":"1993","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cellimm.2015.09.007_b0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0038-1650515","article-title":"T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors","volume":"76","author":"Singer","year":"1996","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-0037-1614081","article-title":"Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects","volume":"84","author":"Reding","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0045","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1046\/j.1538-7836.2003.00251.x","article-title":"Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII","volume":"1","author":"Reding","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0050","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1538-7836.2004.00850.x","article-title":"Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII","volume":"2","author":"Reding","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0055","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1538-7836.2005.01309.x","article-title":"Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII","volume":"3","author":"Jones","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1055\/s-0037-1613257","article-title":"Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients","volume":"88","author":"Reding","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0065","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood-2009-01-200725","article-title":"Lineages of human T-cell clones, including T helper 17\/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses","volume":"114","author":"Ettinger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2015.09.007_b0070","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1073\/pnas.89.9.3795","article-title":"Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals","volume":"89","author":"Algiman","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2015.09.007_b0075","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1172\/JCI117489","article-title":"Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies","volume":"94","author":"Gilles","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2015.09.007_b0080","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2014-12-618991","article-title":"Factor VIII inhibitor: affinity is the clue","volume":"125","author":"Jacquemin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2015.09.007_b0085","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2015.09.007_b0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group","volume":"328","author":"Lusher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2015.09.007_b0095","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1055\/s-0037-1615061","article-title":"Factor VIII inhibitors in mild and moderate-severity haemophilia A","volume":"79","author":"Hay","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1055\/s-0038-1649786","article-title":"Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin","volume":"74","author":"Santagostino","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0105","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood.V89.12.4371","article-title":"The missense mutation Arg593 3 Cys is related to antibody formation in a patient with mild hemophilia A","volume":"89","author":"Fijnvandraat","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2015.09.007_b0110","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.V93.7.2267","article-title":"Anti-factor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A","volume":"93","author":"Peerlinck","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2015.09.007_b0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-0037-1614627","article-title":"Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes","volume":"82","author":"Gilles","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0120","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2002-05-1369","article-title":"CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild\/moderate hemophilia A","volume":"101","author":"Jacquemin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2015.09.007_b0125","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/j.1538-7836.2007.02762.x","article-title":"T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide","author":"James","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2516.2008.01905.x","article-title":"HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P","volume":"16","author":"Ettinger","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.cellimm.2015.09.007_b0135","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1538-7836.2011.04202.x","article-title":"T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site","volume":"9","author":"James","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0140","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa075760","article-title":"Inhibitors of factor VIII in black patients with hemophilia","volume":"360","author":"Viel","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2015.09.007_b0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","article-title":"Inhibitors occur more frequently in African\u2013American and Latino haemophiliacs","volume":"4","author":"Aledort","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.cellimm.2015.09.007_b0150","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1365-2516.2009.02058.x","article-title":"Hemophilia inhibitor S: risk factors for inhibitor formation in haemophilia: a prevalent case\u2013control study","volume":"15","author":"Ragni","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.cellimm.2015.09.007_b0155","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3270","article-title":"Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A","volume":"19","author":"Pandey","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2015.09.007_b0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","article-title":"Hemophilia inhibitor research study I: F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity","volume":"18","author":"Miller","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.cellimm.2015.09.007_b0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.12004","article-title":"Hemophilia inhibitor genetics study combined cohort. F8 haplotype and inhibitor risk: results from the hemophilia inhibitor genetics study (HIGS) combined cohort","volume":"19","author":"Schwarz","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.cellimm.2015.09.007_b0170","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-09-599365","article-title":"Factor VIII gene variants and inhibitor risk in African American hemophilia A patients","author":"Gunasekera","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2015.09.007_b0175","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive FVIII infusion in haemophiliac with factor VIII inhibitor, high responder","volume":"2","author":"Brackmann","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.cellimm.2015.09.007_b0180","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0092-8674(90)90420-J","article-title":"Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity","volume":"63","author":"Webb","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.cellimm.2015.09.007_b0185","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1126\/science.1900951","article-title":"Peripheral selection of the T cell repertoire","volume":"251","author":"Rocha","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2015.09.007_b0190","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1538-7836.2011.04267.x","article-title":"Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells","volume":"9","author":"Pautard","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cellimm.2015.09.007_b0195","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874915300198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874915300198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:54:26Z","timestamp":1757804066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874915300198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":39,"alternative-id":["S0008874915300198"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2015.09.007","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T cell response to FVIII","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2015.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}